Additionally, HBEGF, an EGFR ligand intensively involved in cancer progression, was shown to be the main mediator of epithelial cells and AM cells affecting other cell types [54], and may serve as a potential target for early stage LUAD treatment (Fig. 10A). This evidence concerns the gene HBEGF and cancer.